Literature DB >> 32151942

A prospective study of coffee and tea consumption and the risk of glioma in the UK Biobank.

Jordan H Creed1, Stephanie A Smith-Warner2, Travis A Gerke1, Kathleen M Egan3.   

Abstract

BACKGROUND: Coffee and tea have been hypothesised to reduce the risk of some cancers; however, their impact on glioma is less well studied.
METHODS: We examined associations between self-reported intake of tea and coffee in relation to glioma risk in the UK Biobank. We identified 487 incident glioma cases among 379,259 participants. Hazard ratios (HR) and 95% confidence intervals (CI) for glioma according to caffeinated beverage consumption were calculated using Cox proportional hazards regression with adjustment for age, gender, race and education; daily cups of tea or coffee were included in models considering the other beverage.
RESULTS: Consuming 4 or more cups of tea was associated with reduced risk of glioma when compared to no tea consumption (HR = 0.69; 95% CI, 0.51-0.94). A significant inverse association was observed for glioblastoma (HR = 0.93 per 1 cup/d increment; 95% CI, 0.89-0.98) and among males for all gliomas combined (HR = 0.95 per 1 cup/d increment; 95% CI, 0.90-1.00). A suggestive inverse association was also observed with greater consumption of coffee (HR = 0.71; 95% CI, 0.49-1.05 for >4 versus 0 cups/d). Results were not materially changed with further adjustment for smoking, alcohol and body mass index. Associations were similar in 2-year and 3-year lagged analyses.
CONCLUSIONS: In this prospective study, we found a significant inverse association between tea consumption and the risk of developing glioma, and a suggestive inverse association for the consumption of coffee. Further investigation on the possible preventive role of caffeine in glioma is warranted.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Caffeine; Coffee; Cohort; Glioblastoma; Glioma; Tea; UK Biobank

Mesh:

Substances:

Year:  2020        PMID: 32151942     DOI: 10.1016/j.ejca.2020.01.012

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  Epidemiology of Glioblastoma Multiforme-Literature Review.

Authors:  Szymon Grochans; Anna Maria Cybulska; Donata Simińska; Jan Korbecki; Klaudyna Kojder; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

Review 2.  Daily Lifestyle Modifications to Improve Quality of Life and Survival in Glioblastoma: A Review.

Authors:  Sarah Travers; N Scott Litofsky
Journal:  Brain Sci       Date:  2021-04-23

3.  The Coffee-Acrylamide Apparent Paradox: An Example of Why the Health Impact of a Specific Compound in a Complex Mixture Should Not Be Evaluated in Isolation.

Authors:  Astrid Nehlig; Rodrigo A Cunha
Journal:  Nutrients       Date:  2020-10-14       Impact factor: 5.717

4.  Dietary Factors and Risk of Glioma in Adults: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies.

Authors:  Weichunbai Zhang; Jing Jiang; Xinyi Li; Yongqi He; Feng Chen; Wenbin Li
Journal:  Front Nutr       Date:  2022-02-14

5.  Association of Coffee and Tea Consumption with the Risk of Asthma: A Prospective Cohort Study from the UK Biobank.

Authors:  Fengyu Lin; Yiqun Zhu; Huaying Liang; Dianwu Li; Danrong Jing; Hong Liu; Pinhua Pan; Yan Zhang
Journal:  Nutrients       Date:  2022-09-28       Impact factor: 6.706

6.  A prospective study of dietary flavonoid intake and risk of glioma in US men and women.

Authors:  Alaina M Bever; Aedin Cassidy; Eric B Rimm; Meir J Stampfer; David J Cote
Journal:  Am J Clin Nutr       Date:  2021-10-04       Impact factor: 8.472

7.  Tea, coffee and risk of glioma.

Authors:  Tomoyuki Kawada
Journal:  EXCLI J       Date:  2020-09-14       Impact factor: 4.068

Review 8.  A Decade of Research on Coffee as an Anticarcinogenic Beverage.

Authors:  Ayelén D Nigra; Anderson J Teodoro; Germán A Gil
Journal:  Oxid Med Cell Longev       Date:  2021-09-15       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.